Cart
sales@molnova.com
CDK9-IN-15
CAS No. 852678-17-2
CDK9-IN-15( —— )
Catalog No. M35446 CAS No. 852678-17-2
CDK9-IN-15 is a potent small molecule CDK9 inhibitor, which can block the phosphorylation of positive transcription elongation factor b (P-TEFb) on the C-terminal region of RNA Poly-II by degradation and inhibition of CDK9, inhibit transcription, and rapidly reduce the level of intracellular mRNA, thereby causing apoptosis of tumor cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 62 | In Stock |
|
| 5MG | 92 | In Stock |
|
| 10MG | 155 | In Stock |
|
| 25MG | 296 | In Stock |
|
| 50MG | 440 | In Stock |
|
| 100MG | 619 | In Stock |
|
| 500MG | 1278 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCDK9-IN-15
-
NoteResearch use only, not for human use.
-
Brief DescriptionCDK9-IN-15 is a potent small molecule CDK9 inhibitor, which can block the phosphorylation of positive transcription elongation factor b (P-TEFb) on the C-terminal region of RNA Poly-II by degradation and inhibition of CDK9, inhibit transcription, and rapidly reduce the level of intracellular mRNA, thereby causing apoptosis of tumor cells.
-
DescriptionCDK9-IN-15 (compound 50) is a potent CDK9 inhibitor.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetCDK
-
RecptorCDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number852678-17-2
-
Formula Weight293.34
-
Molecular FormulaC16H11N3OS
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (426.13 mM; Ultrasonic )
-
SMILESOc1cccc2c(Nc3ncnc4sccc34)cccc12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Van Duyne R, et al. Effect of mimetic CDK9 inhibitors on HIV-1-activated transcription. J Mol Biol. 2013;425(4):812-829.?
molnova catalog
related products
-
Cdk1,2 Inhibitor III
Cdk1/2 Inhibitor III is a selective inhibitor of Cdk1/2 with an IC50 value of 2.1 μM against CDK1/cyclin B.
-
TG003 B
TG003 is a potent Clk1/Sty inhibitor that inhibits Clk1 and Clk4, inhibits cancer cell growth and induces apoptosis, and can be used in the study of Duchenne muscular dystrophy.
-
Senexin C
Senexin C is a novel orally active and specific CDK8/19 inhibitor with potential anticancer activity.Senexin C is more metabolically stable and potent than Senexin B. Senexin C inhibits the growth of MV4-11 leukaemia cells.
